What FDA's PCAC briefing documents actually propose

The agency published its position before the meeting. It is worth reading directly.

Update, September 14, 2026: FDA's Pharmacy Compounding Advisory Committee met on July 23–24, 2026. It voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the Section 503A bulk drug substances list. It voted against recommending emideltide (DSIP). The committee is advisory. As of September 14, 2026, FDA has not made a final decision. The rest of this article was written before the meeting.

TL;DR

• Before the meeting, FDA proposed that none of the seven peptides under review be added to the 503A Bulks List.
• The proposal covers both chemical forms of each substance — fourteen entries in total.
• The committee then voted to recommend six of the seven peptides. The staff proposal and the committee votes are advisory. As of September 14, 2026, FDA has not made a final decision.

What the PCAC briefing documents say about peptides

FDA proposes that none of the seven peptides be included on the 503A Bulks List. That language appears in the "Points to Consider" section of the agency's briefing document, which lists each substance in both its free base and acetate form (FDA Briefing Document, 2026). Fourteen entries, fourteen proposals not to include.

A briefing document is the agency's homework, published before the meeting.

Which peptides is the PCAC reviewing in July 2026

The meeting ran July 23-24, 2026 and split the substances across two days. On July 23 the committee discussed BPC-157, KPV, TB-500, and MOTS-c. On July 24 it discussed Emideltide (also called DSIP, in plain English: a sleep-related peptide), Epitalon, and Semax (FDA Advisory Committee Calendar, 2026).

Each substance was reviewed against a named use. TB-500 was evaluated for wound healing, MOTS-c for obesity and osteoporosis, Epitalon for insomnia.

How the evaluation works

FDA weighs four criteria set by a 2019 final rule. How well is the substance chemically characterized? What safety issues does its use raise? What evidence of effectiveness exists? And how has it historically been used in compounding? The agency applies these as a balancing test.

Think of it as four gauges read together rather than a single pass-fail score. A thin record on one gauge is not automatically disqualifying, but it has to be offset elsewhere.

Does a PCAC recommendation change peptide access

It does not. Advisory committees provide independent, non-binding advice, and FDA generally follows their recommendations but is not legally bound to do so. The agency states plainly that it does not intend to issue a final determination until committee input is considered and all reviews are finalized.

There is also a detail worth noting. Several nominations were withdrawn by the nominators, including Wells Pharmacy Network and LDT Health Solutions on behalf of the International Peptide Society. FDA elected to proceed with the presentations anyway.

What to know before drawing conclusions

Nothing about current access changes because a briefing document published. A meeting agenda or a committee vote does not change a substance's compounding status. FDA makes the final decision. Headlines that treat a proposal as a decision are moving faster than the process does.

The Halftime POV

We read the primary documents rather than the coverage of them, and we tell you what they say even when the direction is unwelcome. The honest read here is that FDA's stated position going into this meeting was restrictive. We update our formulary when rules actually change, never in anticipation of them.

Related reading:

• PCAC July 2026 meeting: what the advisory committee is reviewing
• The PCAC advisory committee explained
• The FDA 503A bulks list, explained
• Why some peptides are still Category 2
• 12 peptides removed from FDA restriction in 2026

---

FAQ

Q: What do the FDA briefing documents say about peptides? A: In the Points to Consider section of its July 2026 briefing document, FDA proposes that each of the seven peptides under review not be included on the 503A Bulks List. The proposal covers both the free base and the acetate form of every substance, which is fourteen entries in total.

Q: Which peptides did the PCAC review in July 2026? A: On July 23, 2026 the committee took up BPC-157, KPV, TB-500, and MOTS-c. On July 24 it took up Emideltide (also called DSIP), Epitalon, and Semax. FDA reviewed each substance against a specific proposed use, such as wound healing for TB-500 and insomnia for Epitalon.

Q: Does a PCAC recommendation change peptide access? A: No. Advisory committees give FDA non-binding advice. FDA generally follows that advice but is not legally required to do so, and the agency has said it will not issue a final determination until the advisory process concludes and its reviews are complete. The committee met on July 23-24, 2026. As of September 14, 2026, FDA has not made a final decision.

Q: Why is FDA reviewing peptides whose nominations were withdrawn? A: The briefing document notes that the nominators withdrew several nominations, and that FDA elected to proceed with the presentations anyway. Once a substance is under evaluation, the agency can carry the review forward on its own initiative.

---

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary.

Get started

We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.

---

Sources

• FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (2026)
• FDA — PCAC Briefing Document Introduction, July 23-24, 2026 (2026)
• FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (2026)

---